Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
| ▸ | MME | P08473 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA3 | P07451 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP14 | P50281 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6931337 | 1.00 | FOLH1 (0.64) | FOLH1PPARAMMEPPARGCA12 | |
| SCHEMBL28001170 | 1.00 | FOLH1 (0.64) | FOLH1PPARAMMEPPARGCA12 | |
| SCHEMBL18555446 | 0.91 | FOLH1 (0.55) | FOLH1PPARAMMEPPARGCA12 | |
| SCHEMBL7318248 | 0.91 | GNPAT (0.61) | FOLH1PPARAMMEPPARGMMP9 | |
| SCHEMBL7318238 | 0.91 | GNPAT (0.61) | FOLH1PPARAMMEPPARGMMP9 | |
| SCHEMBL23875428 | 0.88 | CA12 (0.51) | FOLH1PPARAMMEPPARGCA12 | |
| SCHEMBL14544543 | 0.88 | CA12 (0.55) | FOLH1PPARAMMECA12CA1 | |
| SCHEMBL15338721 | 0.88 | CA12 (0.51) | FOLH1PPARAMMEPPARGCA12 | |
| SCHEMBL13611910 | 0.87 | CA12 (0.57) | FOLH1PPARAMMECA12CA1 | |
| SCHEMBL27258224 | 0.87 | CA12 (0.57) | FOLH1PPARAMMECA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114656372-B | P-phenylenediamine bridging compound and application thereof in preparation of medicines for treating sugar metabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-114573476-B | Linear head-tail diamine bridging compound and application thereof in preparation of medicines for treating sugar metabolic disorder diseases | 广州药本君安医药科技股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114656371-B | 1, 4-cyclohexanediamine bridged compounds and their use in the treatment of disorders of glucose metabolism | 广州药本君安医药科技股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-114656371-A | 1, 4-cyclohexanediamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114656372-A | P-phenylenediamine bridged compound and application thereof in preparation of medicines for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114573476-A | Linear head-tail diamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-112500314-B | Compound, preparation method thereof and application thereof in preparing medicament for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-112500314-A | Compound, preparation method thereof and application thereof in preparing medicament for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20110130349-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7838548-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-7550501-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| EP-1697389-A4 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | EISAI R&D MAN CO LTD (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7202234-B2 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | EISAI CO., LTD. (JP) | 2007-04-10 | — | — | US | disclosed |
| EP-1697389-A2 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20050113345-A1 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| WO-2005039504-A2 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | EISAI CO., LTD. (JP) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | TLR2, TLR6, TLR3 | FOLH1 1031/4885PPARA 203/4885MME 2053/4885 |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | TLR2, TLR6, TLR3 | FOLH1 1031/4885PPARA 203/4885MME 2053/4885 |
| US-20050113345-A1 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | TLR2, TLR6, TLR3 | FOLH1 1031/4885PPARA 203/4885MME 2053/4885 |
| US-20110130349-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | TLR2, TLR6, TLR3 | FOLH1 1031/4885PPARA 203/4885MME 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.